




Figure 1A




Figure 1B






Figure 1C

NCI-H460-CLDN18.2 and human PBMC co-inoculated tumor model



*: vs Isotype control $p < 0.05$; **: vs Isotype control $p < 0.01$; ##: vs AM4B6 $p < 0.01$


Figure 2



** : vs isotype control $p < 0.01$; ## : vs 18B10 $p < 0.01$

Figure 3

MC38-CLDN18.2 syngeneic tumor model



*: vs isotype control $p < 0.05$; **: vs isotype control $p < 0.01$; #: vs 18B10 $p < 0.01$.

Figure 4

CT26-CLDN18.2 syngeneic tumor model




Figure 5A




Figure 5B




Figure 6A




Figure 6B

NUGC4-hCLDN18.2 and human PBMC co-inoculation tumor model




Figure 7

MFC-hCLDN18.2 syngeneic tumor model




Figure 8